<DOC>
	<DOCNO>NCT00990236</DOCNO>
	<brief_summary>The risk develop blood clot occur 60 % critical care patient . Many time enoxaparin ( Lovenox® ) give patient higher risk develop clot legs lung . Recent data suggest standard dose Lovenox may fully prevent development clot especially critically ill obese patient . Routine enoxaparin dose also result bleed complication . Thrombelastography ( TEG® ) use measure blood clot . The purpose study : - learn TEG® good guide physician prescribe effective dose Lovenox compare standard dos recommend drug company prevent blood clot develop legs lung , - compare development blood clot patient receive standard dose enoxaparin compare patient receive TEG® guide dose enoxaparin . - determine TEG guide dose result decrease bleed complication compare standard dosing .</brief_summary>
	<brief_title>Thrombelastography Based Dosing Enoxaparin</brief_title>
	<detailed_description>Hypothesis : Enoxaparin dose maintain TEG® ΔR great 1.0 minute decrease incidence DVT compare standard dosing . Initiation enoxaparin thromboprophylaxis do treatment team . Once enrol , subject randomize continue receive standard dose enoxaparin ( 30 mg twice daily ) variable TEG® guide enoxaparin dosing . The treatment team subject blind regard arm patient enrol . Patient characteristic : age , gender , body mass index ( BMI ) , comorbidities , Acute Physiology Chronic Health Evaluation II score ( APACHE II ) , injury , operation collect . As part standard protocol ICU , patient undergo weekly ultrasound duplex examination low extremity presence deep venous thrombosis . A baseline TEG® complete patient enrol study . The blood drawn four six hour morning dose administer , correspond maximum tissue level enoxaparin . TEG® assay run duplicate patient , without heparinase , negate effect enoxaparin assay . Those patient randomize control arm study TEG® perform baseline daily one week , twice weekly . The twice weekly TEG® assay do patient discharge inpatient care enoxaparin discontinue treatment team . No adjustment make enoxaparin dosing . Patients TEG® guide enoxaparin dose arm start treatment order primary treatment team . After second TEG® , dose enoxaparin adjust 10 mg increment per dose order reach target ΔR 1.0 1.4 minute . If initial ΔR great 1.4 minute , dose enoxaparin decrease 10 mg increment target ΔR achieve . Patients TEGs® perform daily adjustment dose target ΔR reach . Once target ΔR achieve , TEG® do twice weekly patient discharge inpatient care enoxaparin discontinue treatment team . All patient assess daily study personnel bleed complication . If bleeding complication occur , subject withdraw study . If interim analysis identifies significant difference bleed complication group study terminate .</detailed_description>
	<criteria>Inpatient initiate enoxaparin thromboprophylaxis Age great 15 year Unable obtain consent patient ARR Presence : intracranial hemorrhage , brain injury Receiving therapeutic dose enoxaparin Receiving form anticoagulation Receiving nonstandard dose regimen enoxaparin</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>deep vein thrombosis</keyword>
	<keyword>superficial venous thrombosis</keyword>
	<keyword>pulmonary embolus</keyword>
</DOC>